Phenotypic profile of alternative activation marker CD163 is different in Alzheimer's and Parkinson's disease

Peixuan Pey1, Ronald K B Pearce, Michail E Kalaitzakis

  • 1Neuropathology Unit, Division of Brain Sciences, Department of Medicine, Imperial College London, Charing Cross Campus, St Dunstan's Road, London, UK. peixuan.pey05@imperial.ac.uk.

Abstract

Insights

Microglia show increased CD163 expression in Alzheimer's and Parkinson's diseases, particularly around amyloid plaques in AD. This suggests a potential peripheral origin for some activated microglia in neurodegeneration.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Microglial activation is a common feature in Alzheimer's (AD) and Parkinson's diseases (PD).
  • Focus is shifting towards alternative microglial activation states that promote tissue repair.
  • CD163, a scavenger receptor with immunoregulatory function, is studied in this context.

Purpose of the Study:

  • To investigate the distribution and association of CD163 immunoreactivity in microglia in AD and PD.
  • To compare CD163 expression patterns between AD, PD, and control cases.
  • To explore the potential origin and function of CD163-positive microglia.

Main Methods:

  • Immunohistochemistry was used to assess CD163 immunoreactivity.
  • 31 AD cases, 27 PD cases, and 16 control cases were analyzed.
  • Double immunofluorescence was employed to examine associations with pathological hallmarks and phagocytic markers (CD68).

Main Results:

  • CD163 immunoreactivity was present in parenchymal microglia in all AD cases and to a lesser extent in PD cases.
  • Prominent CD163 staining was observed in AD cortices and PD brainstems.
  • CD163-positive microglia were associated with Aβ plaques and showed phagocytic capability (CD68+), with evidence of fibrinogen leakage suggesting potential peripheral origin.

Conclusions:

  • Microglial CD163 immunoreactivity is significantly increased in AD compared to PD.
  • CD163-positive microglia are attracted to extracellular pathology like Aβ plaques.
  • Fibrinogen leakage suggests that some CD163-positive microglia may be infiltrating macrophages due to blood-brain barrier compromise.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.8K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K